doi: 10.3389/fimmu.2025.1593263 Received 13 March 2025 Accepted 26 June 2025 Published 21 July 2025 Volume 16 - 2025 Edited by Rajko Reljic, University of London, United Kingdom Reviewed by Angelo Izzo, Royal Prince Alfred Hospital, Australia Angel Alejandro Oate, University of Concepcion, Chile Premanshu Dandapat, Indian Council of Agricultural Research (ICAR), India Updates Copyright 2025 Almujri, Stylianou, Nicastri, Satti, Korompis, Li, De Voss, Polo Peralta Alvarez, Tanner, Bettencourt, Ternette and McShane
Published online October 8, 2022
One primary way to reduce homocysteine levels is through a B12-dependent pathway
Without writing a book and explaining every single trial in detail, Ill share the key takeaway points: Trials #1-4 demonstrated an excellent safety profile in which AOD-9604 was well-tolerated and safe, with next to no difference compared to a placebo Trial #5 saw patients taking the AOD-9604 peptide lose 2.8 kg on a dose of 1 mg, compared to the placebo group losing 0.8 kg over the same time period
Imitola, P
Researchers utilise this compound in laboratory models to investigate lipid metabolism, specifically targeted lipolysis, independent of the classical endocrine pathways associated with full-length hGH